Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Robert Wasserman, M.D.

Chief Medical Officer

Dr. Wasserman was the Chief Medical Officer of Northern Biologics from December 2016 to July 2019 for which he led the clinical development of their lead molecule, MSC-1, a novel anti-LIF monoclonal antibody. Before joining Northern Biologics, Dr. Wasserman was the Global Therapeutic Area Head for Oncology at Covance, a drug development CRO. In addition, he spent 15 years in the pharmaceutical industry, most recently at Roche, including positions in Oncology as the Vice President and Personalized Healthcare Strategic Expert, and as Vice President and Global Head, Translational Medicine.

In these positions, he was responsible for bridging discovery and clinical research through the development of translational medicine strategies, conducting early-phase trials, and supporting the personalized healthcare objectives of the organization. Prior to his employment at Roche, he was the Deputy Director of the Oncology Biomarker group at Novartis after starting his pharmaceutical career at Merck. Dr. Wasserman earned his B.A. from the University of Pennsylvania and M.D. from the Johns Hopkins University School of Medicine. He completed his Pediatric Residency and Pediatric Hematology-Oncology fellowship training at The Children’s Hospital of Philadelphia, University of Pennsylvania and then was on faculty as an Assistant Professor.